Tengion Inc is primarily active in the biotechnology industry.

The main competitors of Tengion Inc in the market include companies such as Organovo Holdings Inc, Organogenesis Holdings Inc, and Cynata Therapeutics Limited.

Tengion Inc is a biotechnology company that was founded in 2003. It focuses on the development of regenerative medicine therapies for a range of diseases. Headquartered in Winston-Salem, North Carolina, Tengion is committed to transforming the lives of patients by creating functional human tissues and organs. The company utilizes its proprietary technology platform, known as Organ Regeneration Platform, to build replacement tissues that can be implanted into the body, potentially offering a long-term solution for patients in need. As a pioneer in the field, Tengion Inc has made significant strides in advancing regenerative medicine and remains dedicated to enhancing patient outcomes globally.

Tengion Inc, a renowned company in the stock market, has achieved several significant milestones. One notable achievement was when the company successfully completed a Phase 1 clinical trial for their groundbreaking product. Tengion Inc also secured important partnerships and collaborations with leading industry players, which helped them expand their market reach and enhance their research and development capabilities. Additionally, the company received regulatory approvals for multiple patents, showcasing their commitment to innovation. Tengion Inc's steadfast dedication to delivering cutting-edge solutions has positioned them as a prominent player in the industry, fostering investor confidence and potential for growth.

Tengion Inc is primarily present in the United States.

Tengion Inc represents values of innovative biotechnology and a commitment to improving patient outcomes. With a corporate philosophy rooted in cutting-edge regenerative medicine, Tengion focuses on developing organ-specific therapies to address unmet medical needs. By leveraging its expertise in biomaterials and cell-based technologies, Tengion aims to revolutionize the field of organ regeneration and transplantation. The company's dedication to scientific advancement, patient well-being, and industry collaboration sets Tengion apart as a leader in regenerative medicine.

Converted at the current exchange rate, the Tengion share trades at 0.00 EUR (0.00 USD).

Tengion Inc is a company specializing in regenerative medicine. It is headquartered in Winston-Salem, North Carolina, USA. Tengion is a clinical development and research company that focuses on the development of organ and tissue regeneration technologies. The business model of Tengion is based on the development of products that help regenerate organs and tissues of patients naturally, rather than replacing them through tissue transplantation. The company utilizes special technologies that allow for the cultivation of regenerative cells in vitro from patient tissue samples. These cells are then incorporated into a scaffold or matrix to form new tissue. Tengion operates in two main divisions: Regenerative Medicine and Medical Devices. The Regenerative Medicine division involves work on regenerative technologies for the restoration of organs and tissues. The Medical Devices division encompasses the development and commercialization of medical devices for endoscopy. The company has several products in development, including the Neo-Kidney Augment, a technology for regenerating kidney function in patients with chronic kidney insufficiency. This product is currently in clinical development and has the potential to reduce the need for frequent dialysis in patients with kidney problems. Another product in Tengion's pipeline is the Esophagus Regeneration, which enables regeneration of the esophagus for patients with Barrett's esophagus and esophageal cancer. Tengion works closely with the FDA and other regulatory agencies to ensure that its products are safe and effective. The company also has a partnership with Wake Forest University School of Medicine to conduct proof-of-concept studies for its technologies. Tengion is a pioneer in regenerative medicine and aims to play a major role in the development of technologies that can regenerate the organs and tissues of patients. The company has the potential to change the way we treat medical issues related to organ and tissue damage. With its innovative products and technologies, Tengion is on track to become a leading provider in regenerative medicine and improve the lives of millions of people worldwide. The company Tengion Inc specializes in regenerative medicine. It is based in Winston-Salem, North Carolina, USA and focuses on the development of organ and tissue regeneration technologies. Its business model involves developing products that regenerate organs and tissues naturally, rather than relying on transplants. Tengion uses special technologies to cultivate regenerative cells from patient tissue samples and incorporates them into a scaffold or matrix to create new tissue. The company operates in two main divisions: Regenerative Medicine and Medical Devices, with a focus on organ and tissue restoration and endoscopy devices respectively. Tengion has several products in development, including the Neo-Kidney Augment for regenerating kidney function and the Esophagus Regeneration for patients with Barrett's esophagus and esophageal cancer. The company works closely with regulatory agencies, such as the FDA, and has a partnership with Wake Forest University School of Medicine for proof-of-concept studies. Tengion is a pioneer in regenerative medicine and aims to revolutionize the treatment of organ and tissue damage. The company has the potential to become a leading provider in the field and improve the lives of millions worldwide.

The revenue cannot currently be calculated for Tengion.

The profit cannot currently be calculated for Tengion.

The P/E ratio cannot be calculated for Tengion at the moment.

The P/S cannot be calculated for Tengion currently.

The Eulerpool Quality Score for Tengion is 2/10.

The ISIN of Tengion is US88034G2084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Tengion is A1JZR2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Tengion is TNGNQ. The ticker symbol is used to trade Tengion shares on the stock exchange.

Tengion paid dividends every year for the past 0 years.

Tengion is assigned to the 'Health' sector.

The dividends of Tengion are distributed in USD.